ALLARITY THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6459 USD | -4.00% |
|
-19.10% | -94.19% |
Presenter SpeechLars Lüthjohan Jensen (Attendees)Good morning, shareholders. It's now 10:00, a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
Calendar
May. 14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.6728
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -94.19% | 208K | |
| +9.40% | 114B | |
| +11.49% | 104B | |
| -14.09% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.32% | 17.89B | |
| +6.87% | 14.28B | |
| +35.25% | 12.55B |
- Stock Market
- Equities
- ALLR Stock
- News Allarity Therapeutics, Inc.
- Transcript : Allarity Therapeutics A/S - Shareholder/Analyst Call
